Advertisement

Topics

MyoKardia, Inc. Company Profile

12:05 EDT 25th June 2018 | BioPortfolio

MyoKardia is dedicated to revolutionizing the treatment of genetic cardiovascular disease. The company’s proprietary platform combines recent breakthroughs in muscle biology with leading-edge cardiovascular disease genetics. This personalized, genetically targeted approach focuses on the underlying cause of disease and has the potential to drastically improve the treatment of cardiomyopathies, and ultimately a broader spectrum of cardiovascular disease, including heart failure. Founded by world leaders in muscle biology and cardiovascular disease genetics, MyoKardia was launched in 2012 with funding from leading life sciences investor, Third Rock Ventures. For more information, please visit www.myokardia.com.


News Articles [12 Associated News Articles listed on BioPortfolio]

MyoKardia Announces Pricing of Public Offering of Common Stock

MyoKardia (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the pricing of an u...

MyoKardia nets $172.7mm via FOPO

Cardiovascular disease-focused MyoKardia Inc. netted $172.7mm through the follow-on public offering of 3.75mm common shares at $49 each. (Collaboration partner Sanofi purchased 150k shares in the offe...

Follow-on offering raises $184M for MyoKardia

A follow-on offering brought in $184 million for MyoKardia.  -More- 

MyoKardia begins dosing in phase 2 HCM trial of Mavacamten

MyoKardia has started dosing in its phase 2 MAVERICK-HCM clinical trial of mavacamten, the company’s oral, allosteric modulator of cardiac myosin mavacamten candidate in symptomatic non-obstructive ...

MyoKardia Sees Positive Results in Mid-Stage Heart Trial

MyoKardia Inc. revealed positive results from a mid-stage obstructive hypertrophic cardiomyopathy trial.

MyoKardia prices $184M follow-on

MyoKardia's mavacamten meets in low-dose cohort of Phase II for cardiomyopathy

MyoKardia's (MYOK) CEO Tassos Gianakakos on Q4 2017 Results - Earnings Call Transcript

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

MyoKardia, Inc.

MyoKardia is dedicated to revolutionizing the treatment of genetic cardiovascular disease. The company’s proprietary platform combines recent breakthroughs in muscle biology ...

More Information about "MyoKardia, Inc." on BioPortfolio

We have published hundreds of MyoKardia, Inc. news stories on BioPortfolio along with dozens of MyoKardia, Inc. Clinical Trials and PubMed Articles about MyoKardia, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of MyoKardia, Inc. Companies in our database. You can also find out about relevant MyoKardia, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...


Corporate Database Quicklinks



Searches Linking to this Company Record